Advertisement

PharmacoEconomics

, Volume 29, Issue 3, pp 175–187 | Cite as

Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations

  • Pieter H.M. van Baal
  • Albert Wong
  • Laurentius C.J. Slobbe
  • Johan J. Polder
  • Werner B.F. Brouwer
  • G. Ardine de Wit
Leading Article Standardizing Indirect Medical Costs

Abstract

A shortcoming of many economic evaluations is that they do not include all medical costs in life-years gained (also termed indirect medical costs). One of the reasons for this is the practical difficulties in the estimation of these costs. While some methods have been proposed to estimate indirect medical costs in a standardized manner, these methods fail to take into account that not all costs in life-years gained can be estimated in such a way. Costs in lifeyears gained caused by diseases related to the intervention are difficult to estimate in a standardized manner and should always be explicitly modelled. However, costs of all other (unrelated) diseases in life-years gained can be estimated in such a way.

We propose a conceptual model of how to estimate costs of unrelated diseases in life-years gained in a standardized manner. Furthermore, we describe how we estimated the parameters of this conceptual model using various data sources and studies conducted in the Netherlands. Results of the estimates are embedded in a software package called ‘Practical Application to Include future Disease costs’ (PAID 1.0). PAID 1.0 is available as a Microsoft® Excel tool (available as Supplemental Digital Content via a link in this article) and enables researchers to ‘switch off’ those disease categories that were already included in their own analysis and to estimate future healthcare costs of all other diseases for incorporation in their economic evaluations.

We assumed that total healthcare expenditure can be explained by age, sex and time to death, while the relationship between costs and these three variables differs per disease. To estimate values for age- and sex-specific per capita health expenditure per disease and healthcare provider stratified by time to death we used Dutch cost-of-illness (COI) data for the year 2005 as a backbone. The COI data consisted of age- and sex-specific per capita health expenditure uniquely attributed to 107 disease categories and eight healthcare provider categories. Since the Dutch COI figures do not distinguish between costs of those who die at a certain age (decedents) and those who survive that age (survivors), we decomposed average per capita expenditure into parts that are attributable to decedents and survivors, respectively, using other data sources.

Keywords

Economic Evaluation Health Expenditure Healthcare Expenditure Supplemental Digital Content Hospital Expenditure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The study was supported by a grant from the Dutch National Institute for Public Health and the Environment Strategic Research Fund (SOR S/260186/01/FU) and the Dutch Ministry of Health, Welfare and Sports, with full freedom of research and publication. The authors have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997 Feb; 16 (1): 1–31PubMedCrossRefGoogle Scholar
  2. 2.
    Meltzer D, Egleston B, Stoffel D, et al. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care 2000 Jun; 38 (6): 679–85PubMedCrossRefGoogle Scholar
  3. 3.
    Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ 2004 May; 13 (5): 417–27PubMedCrossRefGoogle Scholar
  4. 4.
    van Baal PH, Feenstra TL, Hoogenveen RT, et al. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’ cost-utility ratio. Health Econ 2007 Apr; 16 (4): 421–33PubMedCrossRefGoogle Scholar
  5. 5.
    Lee RH. Future costs in cost effectiveness analysis. J Health Econ 2008 Jul; 27 (4): 809–18PubMedCrossRefGoogle Scholar
  6. 6.
    Meltzer D. Response to ‘Future costs and the future of cost-effectiveness analysis’. J Health Econ 2008 Jul; 27 (4): 822–5PubMedCrossRefGoogle Scholar
  7. 7.
    Feenstra TL, van Baal PH, Gandjour A, et al. Future costs in economic evaluation: a comment on Lee. J Health Econ 2008 Dec; 27 (6): 1645–9; discussion 1650–1PubMedCrossRefGoogle Scholar
  8. 8.
    Rappange DR, van Baal PH, van Exel NJ, et al. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics 2008; 26 (10): 815–30PubMedCrossRefGoogle Scholar
  9. 9.
    National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 JunGoogle Scholar
  10. 10.
    Rapport Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie. Diemen: College voor Zorgverzekeringen, 2006Google Scholar
  11. 11.
    van Baal PHM, Feenstra TL, Polder JJ, et al. Economic evaluation and the postponement of health care costs. Health Econ. Epub 2010 Apr 5Google Scholar
  12. 12.
    Manns B, Meltzer D, Taub K, et al. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Econ 2003 Nov; 12 (11): 949–58PubMedCrossRefGoogle Scholar
  13. 13.
    de Kok I, Polder J, Habbema J, et al. The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening. Br J Cancer 2009; 100 (8): 1240–4PubMedCrossRefGoogle Scholar
  14. 14.
    van den Berg M, van Baal PH, Tariq L, et al. The cost-effectiveness of increasing alcohol taxes: a modelling study. BMC Med 2008 Nov 28; 6: 36PubMedCrossRefGoogle Scholar
  15. 15.
    van Baal PH, van den Berg M, Hoogenveen RT, et al. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health 2008 Dec; 11 (7): 1033–40PubMedCrossRefGoogle Scholar
  16. 16.
    Zweifel P, Felder S, Meiers M. Ageing of population and health care expenditure: a red herring? Health Econ 1999 Sep; 8 (6): 485–96PubMedCrossRefGoogle Scholar
  17. 17.
    Polder JJ, Barendregt JJ, van Oers H. Health care costs in the last year of life: the Dutch experience. Soc Sci Med 2006 Oct; 63 (7): 1720–31PubMedCrossRefGoogle Scholar
  18. 18.
    Seshamani M, Gray A. Ageing and health-care expenditure: the red herring argument revisited. Health Econ 2004 Apr; 13 (4): 303–14PubMedCrossRefGoogle Scholar
  19. 19.
    Hakkinen U, Martikainen P, Noro A, et al. Aging, health expenditure, proximity to death, and income in Finland. Health Econ Policy Law 2008 Apr; 3 (Pt 2): 165–95PubMedGoogle Scholar
  20. 20.
    O’Neill C, Groom L, Avery AJ, et al. Age and proximity to death as predictors of GP care costs: results from a study of nursing home patients. Health Econ 2000 Dec; 9 (8): 733–8PubMedCrossRefGoogle Scholar
  21. 21.
    Werblow A, Felder S, Zweifel P. Population ageing and health care expenditure: a school of ‘red herrings’? Health Econ 2007 Oct; 16 (10): 1109–26PubMedCrossRefGoogle Scholar
  22. 22.
    Wong A, van Baal PH, Boshuizen HC, et al. Exploring the influence of proximity to death on disease-specific hospital expenditures: a carpaccio of red herrings. Health Econ. Epub 2010 Mar 15Google Scholar
  23. 23.
    Gandjour A, Lauterbach KW. Does prevention save costs? Considering deferral of the expensive last year of life. J Health Econ 2005 Jul; 24 (4): 715–24Google Scholar
  24. 24.
    Poos M, Smit J, Groen J, et al. Kosten van ziekten in Nederland 2005. Bilthoven: RIVM, 2008. RIVM rapport no. 270751019Google Scholar
  25. 25.
    Polder JJ, Meerding WJ, Koopmanschap MA, et al. The cost of sickness in the Netherlands in 1994: the main determinants were advanced age and disabling conditions. Ned Tijdschr Geneeskd 1998 Jul 11; 142 (28): 1607–11PubMedGoogle Scholar
  26. 26.
    Meerding WJ, Bonneux L, Polder JJ, et al. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ 1998 Jul 11; 317 (7151): 111–5PubMedCrossRefGoogle Scholar
  27. 27.
    Slobbe L, Kommer G, Smit J, et al. Kosten van ziekten in Nederland 2003. Zorg voor euro’s-1. Bilthoven: RIVM, 2006Google Scholar
  28. 28.
    Orosz E, Morgan D. SHA-based national health accounts in thirteen OECD countries: a comparative analysis. OECD health working papers no. 16. Paris: OECD, 2004 [online]. Available from URL: http://www.oecd.org/dataoecd/10/53/33661480.pdf [Accessed 2010 Jan 1]Google Scholar
  29. 29.
    Voorburg/Heerlen, Netherlands Central Bureau of Statistics 1999 [online]. Available from URL: http://www.statline.nl [Accessed 2010 Jan 1]
  30. 30.
    Heijink R, Noethen M, Renaud T, et al. Cost of illness: an international comparison. Australia, Canada, France, Germany and the Netherlands. Health Policy 2008 Oct; 88 (1): 49–61Google Scholar
  31. 31.
    Payne G, Laporte A, Deber R, et al. Counting backward to health care’s future: using time-to-death modeling to identify changes in end-of-life morbidity and the impact of aging on health care expenditures. Milbank Q 2007; 85 (2): 213–57PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2011

Authors and Affiliations

  • Pieter H.M. van Baal
    • 1
    • 2
  • Albert Wong
    • 1
    • 3
  • Laurentius C.J. Slobbe
    • 4
  • Johan J. Polder
    • 3
    • 4
  • Werner B.F. Brouwer
    • 2
  • G. Ardine de Wit
    • 5
    • 6
  1. 1.Expertise Centre for Methodology and Information ServicesNational Institute for Public Health and the Environment (RIVM)Bilthoventhe Netherlands
  2. 2.Erasmus University Rotterdam, Institute of Health Policy & Management and Institute for Medical Technology AssessmentRotterdamthe Netherlands
  3. 3.Tilburg University, Department TranzoTilburgthe Netherlands
  4. 4.National Institute for Public Health and the Environment, Centre for Public Health ForecastingBilthoventhe Netherlands
  5. 5.National Institute for Public Health and the Environment, Centre for Prevention and Health Services ResearchBilthoventhe Netherlands
  6. 6.Julius Center for Health Sciences and Primary Care, University Medical CenterUtrechtthe Netherlands

Personalised recommendations